This announcement is a separate document:
神州细胞自愿披露关于控股子公司产品SCTB41获得药物临床试验批准通知书的公告
Shenzhou Cell voluntarily disclosed the announcement about the controlling subsidiary company product SCTB41 obtaining the drug clinical trial approval notification.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.